^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

P-ckit-ALLO1

i
Other names: P-ckit-ALLO1, Anti-c-kit CAR-T Cells program, Anti-c-kit CAR-T Cells
Associations
Trials
Company:
Roche
Drug class:
c-KIT-targeted CAR-T immunotherapy
Associations
Trials
almost4years
Anti-c-kit CAR-T Cells Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant Conditioning (ASGCT 2022)
Conditioning regimens typically consist of high doses of genotoxic radiation or busulfan that can lead to life-threatening post-transplant complications. Our data indicate that anti-c-kit CAR-T cells can be used as an alternative and less toxic conditioning regimen to facilitate engraftment of autologous HSCs. Future studies aim to further develop our humanized transplant model to assess their use in an allogeneic HSC transplant setting.
CAR T-Cell Therapy
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • THY1 (Thy-1 membrane glycoprotein)
|
KIT expression
|
busulfan • P-ckit-ALLO1
almost5years
[VIRTUAL] Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning (ASGCT 2021)
These conditioning regimens typically consist of high doses of genotoxic radiation or busulfan that can lead to life-threatening post-transplant complications. To compare the activity of CAR 1 and CAR 2 in a transplant model we are currently performing a full allogeneic transplant study in huNSG mice involving CAR-T cell-mediated depletion of engrafted human stem cells, safety switch activation to clear the CAR-T cells, followed by engraftment of second donor CD34+ cells. We anticipate our results will provide additional strong evidence for use of stem cell-directed CAR-T cells as an alternative and less toxic conditioning regimen to facilitate engraftment of allogeneic and gene-corrected autologous HSCs and to significantly broaden the number of patients eligible for transplant.
Preclinical • CAR T-Cell Therapy
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
KIT expression
|
busulfan • P-ckit-ALLO1